Abstract LEV (levetiracetam), an antiepileptic drug which possesses a unique profile in animal models of seizure and epilepsy, has as its unique binding site in brain, SV2A (synaptic vesicle protein 2A). Previous studies have used a chimaeric and site-specific mutagenesis approach to identify three residues in the putative tenth transmembrane helix of SV2A that, when mutated, alter binding of LEV and related racetam derivatives to SV2A. In the present paper, we report a combined modelling and mutagenesis study that successfully identifies another 11 residues in SV2A that appear to be involved in ligand binding. Sequence analysis and modelling of SV2A suggested residues equivalent to critical functional residues of other MFS (major facilitator superfamily) transporters. Alanine scanning of these and other SV2A residues resulted in the identification of residues affecting racetam binding, including Ile 273 which differentiated between racetam analogues, when mutated to alanine. Integrating mutagenesis results with docking analysis led to the construction of a mutant in which six SV2A residues were replaced with corresponding SV2B residues. This mutant showed racetam ligand-binding affinity intermediate to the affinities observed for SV2A and SV2B.
Introduction
Epilepsy is one of the most common chronic neurological disorders, characterized by recurrent spontaneous seizures [1] . LEV [levetiracetam; (S)-α-ethyl-2-oxo-pyrrolidine acetamide; Keppra TM ] is a second-generation anti-epileptic drug approved for use in 1999 in the U.S.A. LEV and related compounds such as Compound 1 (ucb 30889) [2] and brivaracetam [3] are all similar in structure, containing a central pyrrolidone ring system, and are collectively referred to as racetams. LEV is chemically unrelated to any other currently marketed anti-epileptic drugs, and possesses unique anti-epileptic effects [4] . Studies in the 1990s led to the identification of a unique binding site for LEV in rat brain [5] . Further studies over the last decade demonstrated conclusively that SV2A (synaptic vesicle protein 2A) is the protein-binding site of LEV and related racetams in both rat brain [2, 6, 7] and human brain [8] .
SV2A is the most widely expressed of the three SV2 isoforms [9] [10] [11] . The SV2 proteins are integral membrane proteins of both synaptic vesicles and dense core vesicles. They are homologous with the large and broadly distributed MFS (major facilitator superfamily) of transporters [12] . However, no transport function for SV2 proteins has yet been found.
To improve the understanding of the potential effects of LEV acting via SV2A, we have been studying the mechanism of racetam binding to SV2A. We have reported previously the identification of three residues in TMH (transmembrane helix) 10 of rSV2A (rat SV2A), namely Phe 658 , Gly 659 and Val 661 , whose mutation affects binding of racetams (D. Anderson, J. Shi, J.G. Castaigne, P. Foerch, B. Kenda, P. Michel and B.A. Lynch, unpublished work). Intriguingly, two of these three residues align with critical functional residues in the MFS protein lactose permease from Escherichia coli (LacY), which has an X-ray structure reported [14] . In order to extend our studies of identification of potential binding site residues for LEV and its derivatives, we report in the present paper a combined alignment, modelling and mutagenesis approach, which led to the identification of another 11 residues in rSV2A that appeared to be involved in racetam binding.
Sequence alignment of selected MFS proteins
Construction of an accurate sequence alignment was critical to aid the identification of residues in rSV2A that may be involved in ligand binding or its modulation. Four MFS proteins, for which putative functional residues have been proposed according to mutagenesis experiments, were utilized in the alignment. They were LacY, rOCT (rat organic cation Predicted TMHs are shown in boxes. The DRXGRR, ELYP and PE(S/T) motifs are marked. Dark shade: conserved positions; grey shade, positions with sequence identities greater than 80%; blue shade, reported functional residues; yellow shade, rSV2A residues that showed no change in racetam binding when mutated to alanine; red shade, rSV2A residues that altered racetam binding when mutated to alanine or when alkylated (see the text).
transporter) 1 and 2 and hOAT1 (human organic anion transporter 1). Their selection was based primarily on both the abundance of experimental information of functional residues and the sequence similarity to rSV2A. It is worth noting that LacY is one of the five MFS proteins whose X-ray structures have been determined to date [14] [15] [16] [17] [18] ; its inclusion in the alignment also facilitates the homology modelling of rSV2A.
Knowledge of the TMH boundaries is invaluable for the correct alignment of membrane proteins of low sequence similarity, such as LacY and rSV2A sharing only 14% sequence identity. However, predicting the exact start and end points of TMHs remains a challenging task [19] . It has been shown that consensus approaches offer better prediction confidence at the cost of lower coverage [20, 21] .
In addition, evolutionary information has been used to improve both prediction confidence and sensitivity [22] [23] [24] . In our work, the two types of approaches were combined to offer higher accuracy and coverage. Three TMH-prediction algorithms of distinct underlying methodologies [19, [25] [26] [27] [28] , SOSUI [29, 30] , TMHMM 2.0 [31] and MINNOU [32] , were applied to not only the protein of interest, but also its close homologues. The predicted TMHs of the homologues were mapped to the protein of interest based on sequence alignment, from which a consensus prediction could be derived.
ClustalW [33] failed to produce an acceptable alignment due to low sequence identity and long insertions/deletions in loops connecting adjacent TMHs. FUGUE [34] was used to extract structural environment features, such as secondary structure, accessibility and hydrogen-bonding patterns, from the X-ray structure of LacY (PDB code 1PV6), generating a profile encompassing structural environmentspecific signatures. TMH prediction was performed for rSV2A and each of the four selected MFS proteins using the aforementioned consensus approach; the predicted TMH locations were used as additional constraints by CHORUS (Advanced Protein Modeling, Tripos Inc.), a variant of FUGUE incorporating a progressive alignment strategy adapted from ClustalW, to align the sequences to the structural profile of LacY. The final alignment, including predicted TMHs of rSV2A, is shown in Figure 1 .
A close examination of the alignment revealed three types of motifs that characterize MFS proteins. The DRXGRR motif is probably the best known MFS signature [35] , which forms the major part of loop 2-3 (the loop connecting TMH2 and TMH3) and loop 8-9. A second type of motif, PE(S/T), present in the regions immediately following TMH6 and TMH12, is less well conserved. A third type, ELYP, is conserved in loop 10-11 among sequences other than LacY, but barely recognizable in loop 4-5. It has been widely speculated that an early geneduplication event resulted in the similarity, or 'pseudosymmetry', between the two halves (TMH1-TMH6 and TMH7-TMH12) of an MFS protein [36, 37] . The observation of the three types of motifs at symmetrical locations in both halves is in good agreement with this hypothesis. The multiple constraints imposed by sequence motifs, structural environment preference, TMH prediction and short loops connecting adjacent helices offer high degree of confidence in the alignment, although, relatively speaking, TMH1 and TMH7 have far fewer constraints than the others and are more prone to alignment errors.
Functional residues of the four selected MFS proteins, as reported in literature, are highlighted by blue shading in Figure 1 . The equivalent residues of rSV2A were mutated to alanine, one at a time, and tested for altered racetam binding.
Homology modelling of rSV2A
A homology model of rSV2A was constructed to help propose and prioritize additional mutations. LacY was chosen as the template structure for the modelling of rSV2A because of the large body of reported experimental characterization of LacY at both sequence and structure level [38] . MODELER [39, 40] was used to model rSV2A using the alignment shown in Figure 1 . Note that only the transmembrane regions of rSV2A were modelled, which consisted of residues 137-370, 431-478 and 591-742.
We periodically reviewed mutagenesis and binding results as experiments progressed, using the model of rSV2A to rationalize observations. The structure of Compound 1 was manually docked in the central cavity of the rSV2A model to maximize its contact with residues identified at the time to affect binding. Proposed, but untested, alanine mutations were then ranked and prioritized according to their positions relative to the docked compound. Additional mutations were also proposed periodically based on the evaluation of the rSV2A and the docked compound.
Racetam-binding studies of alanine mutants
Screening of a total of 53 rSV2A mutants transiently expressed in COS-7 cells was performed using [41] . Similarly, alkylation of the equivalent residue in rSV2A (Cys 297 ) abolished the binding to Compound 1. Note that the C297A mutation had no effect on the binding to Compound 1, and the alkylation of this mutant had no effect on Compound 1 binding either.
Ile 273 is aligned with Ala 122 of LacY, which is involved in substrate binding [41] . The I273A mutation had no effect on Compound 1 binding, but drastically reduced the binding of Compound 2. This observation was confirmed for a pair of analogues, Compound 3 and Compound 4, where only the binding of Compound 4 was altered by the I273A mutation (Figure 2) . The same type of analogue differentiation behaviour was observed in rOCT1 after mutating the equivalent residue Trp 218 to phenylalanine, A722V  12  Miscellaneous  WT  -L725A  12  Miscellaneous  WT  -G738A  C-terminus  Miscellaneous  WT  -C656A tyrosine and leucine [42] [43] . All three of these positions in rSV2A, when mutated to alanine, showed altered binding to Compound 1. One of them, I663A, was completely dysfunctional, and we were not able to show binding to the radiolabelled probe, and thus were not able to determine an IC 50 value.
Analysis of the location of functional residues in LacY identified TMH5 as having a particularly large number of functional residues. As a result, we decided to perform mutagenesis of additional residues in this TMH. Two additional residues, Ser 294 and Met 301 , showed altered binding to Compound 1.
In addition to the positions analysed above, we investigated a total of five charged side-chain residues located in the predicted transmembrane regions. Intriguingly, none of these positions except for Lys 694 , which aligns with a LacY functional residue, affected racetam binding to a significant degree when mutated to alanine. Another class of positions mutated were those containing polar side chains in transmembrane regions. These were chosen because of the anticipation that residues with polar side chains might form hydrogen bonds to the racetams, which generally have multiple hydrophilic moieties. However, none of these positions except for Ser 294 , Tyr 462 and Asn 667 , which had already been identified, affected racetam binding to a significant degree when mutated to alanine.
Finally, a number of additional residues, including some predicted in the loops between transmembrane regions, were mutated to alanine. None of these mutations appeared to show any significantly altered racetam-binding properties.
Binding studies of the 6AB mutant
On the basis of the mutagenesis results, the structure of Compound 1 was manually docked into the central cavity of the rSV2A model, maximizing its contact with residues identified to affect binding. Six residues in close proximity to the docked ligand were different between rSV2 isoforms A and B. Those six rSV2B residues were engineered into rSV2A simultaneously, resulting in the 6AB mutant (I273L, C297G, M298I, S458A, F459L and G659C). Compound 5 (structure not currently available), which binds to both rSV2A and rSV2B with different potencies, was assessed on the 6AB mutant. It displayed an affinity (IC 50 20 nM) intermediate between its affinities to rSV2A (IC 50 10 nM) and rSV2B (IC 50 63 nM). This supports further the hypothesis that SV2 ligands bind in the central cavity of SV2, a region analogous to the substrate-binding site in LacY.
Conclusions
Although the mechanism of action of LEV and racetam derivatives on SV2A is still unknown, we were able, by combining theoretical and experimental approaches, to propose a binding site for SV2A racetam ligands. This binding site encompasses residues equivalent to functional residues in other MFS transporters. Successful identification of the racetam-binding region based on the knowledge generated in distantly related MFS proteins supports the hypothesis that, although MFS proteins share low sequence identities, they adopt the same fold and utilize similar mechanisms during the ligand-binding event [44] . Within the racetam-binding region, some mutants were found to differentiate between two classes of SV2A ligands, suggesting that, although these compounds bind to the same region of SV2A, they may engage different residues. Further studies will be conducted to determine whether the binding modes of different SV2A ligands can be inferred from the mutagenesis data combined with molecular modelling analysis. Alternative conformations of SV2A will be taken into account on the basis of the recently published Xray structures of MFS transporters determined in alternative states compared with LacY [16, 18] .
